Follow us on Twitter
twitter icon@FreshPatents


Codon patents

      

This page is updated frequently with new Codon-related patent applications.




 Computationally optimized broadly reactive antigens for human and avian h5n1 influenza patent thumbnailComputationally optimized broadly reactive antigens for human and avian h5n1 influenza
Described herein is the generation of optimized h5n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h5n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on human and avian h5n1 isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


 Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia patent thumbnailTamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof..
Mallinckrodt Llc


 Controlled release hydrocodone formulations patent thumbnailControlled release hydrocodone formulations
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a c12/cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours..
Purdue Pharma L.p.


 Methods of providing analgesia patent thumbnailMethods of providing analgesia
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


 Controlled release hydrocodone formulations patent thumbnailControlled release hydrocodone formulations
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


 Method for suppressing cell growth patent thumbnailMethod for suppressing cell growth
Disclosed is a method for suppressing the growth of a target cell, which is not limited in the type of a target cell and the type of a protein to be expressed in the target cell and needs not any preparatory experiment for determining a codon to be contained in a protein to be expressed in a target cell. Specifically disclosed is a method for suppressing the growth of a target cell, which comprises the steps of: incorporating dna containing a region encoding a protein into the target cell, and allowing a protein encoded by the dna to be expressed in the target cell into which the dna has been incorporated.
Japan Agency For Marine-earth Science And Technology


 Attenuated viruses useful for vaccines patent thumbnailAttenuated viruses useful for vaccines
This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject.
The Research Foundation For The State University Of New York


 Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid patent thumbnailPharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
Provided herein are pharmaceutical compositions, which comprise a 1,2,4-oxadiazole benzoic acid or a pharmaceutically acceptable salt thereof. Further provided herein are certain pharmaceutically acceptable salts of a 1,2,4-oxadiazole benzoic acid and methods for making the same.
Ptc Therapeutics, Inc.


 Chinese medicine prescription capable of treating lung adenocarcinoma patent thumbnailChinese medicine prescription capable of treating lung adenocarcinoma
A chinese medicine prescription capable of treating lung adenocarcinoma is composed of polygala tenuifolia willd, atractylodes macrocephala, angelica sinensis, poria pararadicis, astragalus membranaceus, ziziphus jujaba mill.var.spinosa, codonopsis pilosula, costustoot, radix glycyrrhizae preparata and fresh ginger, and a pharmaceutical residue is filtered and obtained after a water quenching procedure of the aforementioned herbs to provide a water-quenched medicine soup, and a pharmaceutical residue is filtered and obtained after processing the water-quenched pharmaceutical residue by a liquor quenching procedure to obtain a liquor-quenched medicine soup; and the water-quenched medicine soup and the liquor-quenched medicine soup are mixed. The prescription is capable of triggering cell autophagy and reducing cell growth, expansion and metastasis, so as to achieve the effect of lung adenocarcinoma treatment..

 Phage display library patent thumbnailPhage display library
A library of replicating entities, each entity comprises a recombinant vector comprising a randomized nucleic acid sequence, having the reading frame structure [nxx]n [coraa] [nxx]m [nzz]o, or [nzz]o [nxx]m [coraa] [nxx]n. Each nxx is independently a codon encoding for any amino acid except cysteine, coraa is a codon encoding for cysteine or at least one other amino acid, each nzz is independently a codon encoding for any amino acid, and n is an integer from 0 to 40, m is an integer from 1 to 20, o is an integer from 1 to 40, and at least 20 percent of coraa encode for cysteine.
Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.


Compositions for the inactivation of virus replication and methods of making and using the same

Provided herein are recombinant constructs, vectors and expression cassettes including a first promoter which is suitably a trna promoter operably connected to a first polynucleotide encoding a first single guide rna and a second promoter operably connected to a second polynucleotide encoding a cas9 polypeptide. The first single guide rna includes a first portion complementary to a strand of a target sequence of a dna virus and a second portion capable of interacting with the cas9 polypeptide.
Emory University

Pharmaceutical compositions for treating or preventing pain

Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat or prevent pain in a subject, and to reduce or prevent an adverse effect associated with the analgesics.. .
Locl Pharma, Inc.

Treating pain in patients with hepatic impairment

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited

Compositions and methods for making selenocysteine containing polypeptides

Non-naturally occurring trnasec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring trnasec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mrna without the requirement of an secis element.
Yale University

Codon-optimized gene for mutated shrimp luciferase and use thereof

There has been a demand for a codon-optimized gene for the mutated catalytic domain of oplophorus luciferase, which is capable of efficiently expressing a protein both in a cultured animal cell and escherichia coli. There has also been a demand for a substrate coelenterazine analogue showing a higher activity than that of native 19 kda protein.
Jnc Corporation

Treatment of hyperbilirubinemia

The invention relates to a nucleic acid sequence useful in the treatment of hyperbilirubinemia, in particular in the treatment of crigler-najjar syndrome. More particularly, the nucleic acid sequence of the present invention is a codon-optimized ugt1a1 coding sequence..
International Center For Genetic Engineering And Biotechnology

Process for reducing contaminating michael acceptor levels in oxycodone and other compositions

The present invention relates to processes for removal of michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove michael acceptors and the resulting thiol-michael adducts. Certain embodiments of the present invention enable quantification and/or removal of michael acceptors and/or michael acceptor precursors..
Controlled Chemicals, Inc.

Process for improved oxycodone synthesis

Processes for preparing oxycodone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxycodeinone salt in the presence of trifluoroacetic acid and/or a glycol..
Rhodes Technologies

Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.

Design of mrna sequences to control co-translational folding of proteins

This invention relates to optimized heterologous production of properly folded and functional proteins. The present invention provides systems and methods involving determination of the optimal mrna sequence, based on the underlying rates at which codons are translated and folding kinetic of nascent-protein, that maximizes co-translational protein folding of domains in order to maximize the proper folding and quality of the protein produced.
The Penn State Research Foundation

Formulations of nonopioid and confined opioid analgesics

The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse.
Abbvie Inc.

Compositions and methods for making selenocysteine containing polypeptides

Non-naturally occurring trnasec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring trnasec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mrna without the requirement of an secis element.
Yale University

Methods for efficient, expansive, user-defined dna mutagenesis

The presently disclosed subject matter provides methods for the creation of one or more user-defined mutations that can be located anywhere in a target sequence, such as in a gene. These mutations can comprise single mutations, multiple mutations, or a comprehensive codon mutagenesis library, in which all possible single codon substitutions in a gene are created.
The Johns Hopkins University

Heterologous expression of fungal cellobiohydrolase 2 genes in yeast

The present invention provides for heterologous expression of polypeptides encoded by wild-type and codon-optimized cbh2 genes from the organisms cochliobolus heterostrophus, gibberella zeae, irpex lacteus, volvariella volvacea, and piromyces sp. In host cells, such as the yeast saccharomyces cerevisiae.
Stellenbosch University

Ptd-smad7 therapeutics

The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described.
The Regents Of The University Of Colorado, A Body Corporate

Adeno-associated virus vectors for treatment of glycogen storage disease

The present disclosure describes improved adeno-associated virus (aav) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type ia (gsd-ia). Described are recombinant nucleic acid molecules, vectors and recombinant aav that include a g6pc promoter/enhancer, a synthetic intron, a g6pc coding sequence (such as a wild-type or codon-optimized g6pc coding sequence), and stuffer nucleic acid sequence situated between the g6pc promoter/enhancer and the intron, as well as between the intron and the g6pc coding sequence.
University Of Florida Research Foundation, Incorporated

Method of increasing biomass and lipid content in a micro-organism and a genetically modified micro-organism exhibiting enhanced autophagy

According to an embodiment of the invention, there is provided a method of increasing biomass and lipid content in a micro-organism comprising cloning in a vector an exogenous gene sequence selected from the group comprising atg1 gene, atg6 gene, and atg8 gene sequence wherein the sequence is codon optimized for said micro-organism, for inducing autophagy; introducing the vector containing the gene into the genome of the micro-organism to yield a genetically modified micro-organism; and growing the genetically modified micro-organism in suitable medium. According to another embodiment of the invention there is provided a method of increasing biomass and lipid content in a micro-organism exposed to stress, comprising treating the microorganism with an autophagy inducing agent..
Reliance Industries Limited

Method for producing polyunsaturated fatty acids

The invention relates to a method for producing eicosapentanoic acid, docosapentanoic acid and/or docohexanoic acid in transgenic plants. According to said method, the plant is provided with at least one nucleic acid sequence coding for a polypetide with a Δ6 desaturase activity, at least one nucleic acid sequence coding for a polypeptide with a Δ6 elongase activity, at least one nucleic acid sequence coding for a polypeptide with a Δ5 desaturase activity, and at least one nucleic acid sequence coding for a polypeptide with a Δ5 elongase activity, the nucleic acid sequence coding for a polypeptide with a Δ5 elongase activity being modified in relation to the nucleic acid sequence in the organism from which the sequence originates, such that it is adapted to the codon use in at least one type of plant.
Basf Plant Science Gmbh

Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.

Effect of ppegid1c on vegetative growth of fruit trees

The genetic basis for a recessive dwarf trait (dw) in peach (prunus persica) was determined. Using a sequencing-based bulk-segregant mapping strategy, dw was positioned on the distal end of peach chromosome 6.
The United States Of America, As Represented By The Secretary Of Agriculture

Live-attenuated virus and methods of production and use

Presented herein are live-attenuated viruses and methods of generating thereof from a parental virus through a plurality of nucleotide substitutions in the viral genome. The nucleotide substitutions result in a change in codon usage bias within codons of one or more protein encoding sequences and no change in amino acid sequences of the proteins.
The University Of Hong Kong

Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.

Treating pain in patients with hepatic impairment

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited

Sin nombre virus full-length m segment-based dna vaccines

The invention contemplates a new synthetic, codon-optimized sin nombre virus (snv) full-length m gene open reading frame (orf) that encodes a unique consensus amino acid sequence. The snv orf was cloned into a plasmid to form the first stable recombinant snv full-length m gene that elicits neutralizing antibodies.
The United States Of America, As Rep. By The Sec'y Of The Army, For U.s. Army Medical Research Insti

Pharmaceutical compositions for treating or preventing pain

Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat or prevent pain in a subject, and to reduce or prevent an adverse effect associated with the analgesics.. .
Locl Pharma, Inc.



Codon topics:
  • Hydrocodone
  • Nucleic Acid
  • Acetaminophen
  • Carboxylic Acid
  • Benzoic Acid
  • Genetically
  • Recombinant
  • Amino Acid
  • Nucleotide
  • Reverse Transcriptase Inhibitors
  • Reverse Transcriptase Inhibitor
  • Reverse Transcriptase
  • Antibodies
  • Base Sequence
  • Replication


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3057

    file did exist - file did put2173

    6 - 1 - 51